[Frontiers In Bioscience, Landmark, 24, 1462-1476, June 1, 2019]

Regulatory antibodies against GPCR in women ten years after early-onset preeclampsia

Anna Birukov1,2,3,4,5, Hella E.C. Muijsers6, Harald Heidecke7, José T. Drost8, Mark W. Cunnigham Jr.9, Kristin Kraker1,2,3,4,5, Nadine Haase1,2,3,4,5, Alina Frolova10, Dominik N. Müller1,2,3,4,5, Florian Herse1,3,4,5, Angela H.E.M. Maas6, Ralf Dechend1,2,3,4,5,11

1Experimental and Clinical Research Center, a joint cooperation between Max-Delbrück-Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; 2DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany; 3Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; 4Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany; 5Berlin Institute of Health (BIH), Berlin, Germany; 6Radboud University Medical Center, Department of Cardiology, Nijmegen, The Netherlands; 7CellTrend GmbH, Luckenwalde, Germany; 8Saxenburgh Group, department cardiology, Hardenberg, The Netherlands; 9University of Mississippi Medical Center, Department of Pharmacology & Toxicology, Jackson, Mississippi, USA; 10Institute of Molecular Biology and Genetics of NASU, Kyiv, Ukraine; 11Department of Cardiology and Nephrology, HELIOS Klinikum Berlin, Berlin, Germany


1. Abstract
2. Introduction
3. Methods
3.1. Study population
3.2. Laboratory analyses
3.3 Statistical analyses
4. Results
5. Discussion
6. Acknowledgements
7. References


Preeclampsia is associated with an increased cardiovascular risk later in life. Anti-GPCR autoantibodies have been shown to contribute to the development of cardiovascular disease. We investigated whether anti-GPCR autoantibodies are elevated in women with a history of early-onset preeclampsia 8-11 years postpartum, and whether they correlate with clinical outcomes. We investigated data from the Preeclampsia Risk EValuation in FEMales cohort, a retrospective matched case-control study. Anti AT1R-, beta1AR-, ETAR-, PAR1- and CXCR3- autoantibodies were determined in 485 samples by using commercially available ELISA. Women with the lowest combined levels of autoantibodies and a history of early preeclampsia had significantly higher SBP, DBP and MAP (all p<0.001) compared to the controls. The individual titer levels of autoantibodies were not different between controls and former early PE groups 8-11 years postpartum. In conclusion, regulatory autoantibodies alone are not sufficient to explain hypertension or other cardiovascular pathologic conditions, but together with other risk factors such as a previous hypertensive pregnancy, lower levels of autoantibodies are associated with increased blood pressure.


1. B. Sibai, G. Dekker and M. Kupferminc: Pre-eclampsia. Lancet, 365(9461), 785-99 (2005)
DOI: 10.1016/S0140-6736(05)17987-2

2. L. Duley: The global impact of pre-eclampsia and eclampsia. Semin Perinatol, 33(3), 130-7 (2009)
DOI: 10.1053/j.semperi.2009.02.010

3. K. Melchiorre, R. Sharma and B. Thilaganathan: Cardiovascular implications in preeclampsia: an overview. Circulation, 130(8), 703-14 (2014)
DOI: 10.1161/Circulationaha.113.003664

4. L. Bellamy, J. P. Casas, A. D. Hingorani and D. J. Williams: Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ, 335(7627), 974 (2007)
DOI: 10.1136/bmj.39335.385301.BE

5. M. C. Brown, K. E. Best, M. S. Pearce, J. Waugh, S. C. Robson and R. Bell: Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol, 28(1), 1-19 (2013)
DOI: 10.1007/s10654-013-9762-6

6. P. M. Cirillo and B. A. Cohn: Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort. Circulation, 132(13), 1234-42
DOI: Circulationaha.113.003901

7. L. Mosca, E. J. Benjamin, K. Berra, J. L. Bezanson, R. J. Dolor, D. M. Lloyd-Jones, L. K. Newby, I. L. Pina, V. L. Roger, L. J. Shaw, D. Zhao, T. M. Beckie, C. Bushnell, J. D’Armiento, P. M. Kris-Etherton, J. Fang, T. G. Ganiats, A. S. Gomes, C. R. Gracia, C. K. Haan, E. A. Jackson, D. R. Judelson, E. Kelepouris, C. J. Lavie, A. Moore, N. A. Nussmeier, E. Ofili, S. Oparil, P. Ouyang, V. W. Pinn, K. Sherif, S. C. Smith, Jr., G. Sopko, N. Chandra-Strobos, E. M. Urbina, V. Vaccarino and N. K. Wenger: Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation, 123(11), 1243-62
DOI: CIR.0b013e31820faaf8

8. M. F. Piepoli, A. W. Hoes, S. Agewall, C. Albus, C. Brotons, A. L. Catapano, M. T. Cooney, U. Corra, B. Cosyns, C. Deaton, I. Graham, M. S. Hall, F. D. R. Hobbs, M. L. Lochen, H. Lollgen, P. Marques-Vidal, J. Perk, E. Prescott, J. Redon, D. J. Richter, N. Sattar, Y. Smulders, M. Tiberi, H. B. van der Worp, I. van Dis, W. M. M. Verschuren, S. Binno and E. S. C. S. D. Group: 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J, 37(29), 2315-2381 (2016)
DOI: 10.1093/eurheartj/ehw106

9. Y. Xia and R. E. Kellems: Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Rev Clin Immunol, 7(5), 659-74 (2011)
DOI: 10.1586/eci.11.56

10. G. Wallukat and I. Schimke: Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin Immunopathol, 36(3), 351-63 (2014)
DOI: 10.1007/s00281-014-0425-9

11. N. J. Freedman and R. J. Lefkowitz: Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest, 113(10), 1379-82 (2004)
DOI: 10.1172/JCI21748

12. G. Wallukat and A. Wollenberger: Autoantibodies to beta 2-adrenergic receptors with antiadrenergic activity from patients with allergic asthma. J Allergy Clin Immunol, 88(4), 581-7 (1991)

13. G. Wallukat, V. Homuth, T. Fischer, C. Lindschau, B. Horstkamp, A. Jupner, E. Baur, E. Nissen, K. Vetter, D. Neichel, J. W. Dudenhausen, H. Haller and F. C. Luft: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest, 103(7), 945-52 (1999)
DOI: 10.1172/JCI4106

14. R. Dechend, C. Viedt, D. N. Muller, B. Ugele, R. P. Brandes, G. Wallukat, J. K. Park, J. Janke, P. Barta, J. Theuer, A. Fiebeler, V. Homuth, R. Dietz, H. Haller, J. Kreuzer and F. C. Luft: AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation, 107(12), 1632-9 (2003)
DOI: 10.1161/01.CIR.0000058200.90059.B1

15. A. H. Siddiqui, R. A. Irani, S. C. Blackwell, S. M. Ramin, R. E. Kellems and Y. Xia: Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension, 55(2), 386-93 (2010)
DOI: 10.1161/hypertensionaha  .109.140061

16. F. Herse, S. Verlohren, K. Wenzel, J. Pape, D. N. Muller, S. Modrow, G. Wallukat, F. C. Luft, C. W. Redman and R. Dechend: Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension, 53(2), 393-8 (2009)
DOI: 10.1161/hypertensionaha  .108.124115

17. C. A. Hubel, G. Wallukat, M. Wolf, F. Herse, A. Rajakumar, J. M. Roberts, N. Markovic, R. Thadhani, F. C. Luft and R. Dechend: Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension, 49(3), 612-7 (2007)
DOI: 10.1161/01.HYP.0000256565.20983.d4

18. M. R. Parrish, S. R. Murphy, S. Rutland, K. Wallace, K. Wenzel, G. Wallukat, S. Keiser, L. F. Ray, R. Dechend, J. N. Martin, J. P. Granger and B. LaMarca: The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens, 23(8), 911-6 (2010)
DOI: 10.1038/ajh.2010.70

19. J. Brewer, R. Liu, Y. Lu, J. Scott, K. Wallace, G. Wallukat, J. Moseley, F. Herse, R. Dechend, J. N. Martin, Jr. and B. Lamarca: Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy. Hypertension, 62(5), 886-92 (2013)
DOI: 10.1161/hypertensionaha .113.01648

20. M. W. Cunningham, Jr., J. Castillo, T. Ibrahim, D. C. Cornelius, N. Campbell, L. Amaral, V. R. Vaka, N. Usry, J. M. Williams and B. LaMarca: AT1-AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats. Hypertension, 71(5), 886-893 (2018)
DOI: 10.1161/hypertensionaha  .117.10681

21. J. T. Drost, G. Arpaci, J. P. Ottervanger, M. J. de Boer, J. van Eyck, Y. T. van der Schouw and A. H. Maas: Cardiovascular risk factors in women 10 years post early preeclampsia: the Preeclampsia Risk EValuation in FEMales study (PREVFEM). Eur J Prev Cardiol, 19(5), 1138-44 (2012)
DOI: 10.1177/1741826711421079

22. E. Expert Panel on Detection and A. Treatment of High Blood Cholesterol in: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 285(19), 2486-97 (2001)

23. O. Cabral-Marques, A. Marques, L. M. Giil, R. De Vito, J. Rademacher, J. Gunther, T. Lange, J. Y. Humrich, S. Klapa, S. Schinke, L. F. Schimke, G. Marschner, S. Pitann, S. Adler, R. Dechend, D. N. Muller, I. Braicu, J. Sehouli, K. Schulze-Forster, T. Trippel, C. Scheibenbogen, A. Staff, P. R. Mertens, M. Lobel, J. Mastroianni, C. Plattfaut, F. Gieseler, D. Dragun, B. E. Engelhardt, M. J. Fernandez-Cabezudo, H. D. Ochs, B. K. Al-Ramadi, P. Lamprecht, A. Mueller, H. Heidecke and G. Riemekasten: GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. Nat Commun, 9(1), 5224 (2018)
DOI: 10.1038/s41467-018-07598-9

24. D. Ernst, C. Widera, D. Weiberg, T. Derlin, G. Ahrenstorf, G. Sogkas, A. Jablonka, R. E. Schmidt, T. Witte, H. Heidecke and G. Riemekasten: Beta-1-Adrenergic Receptor Antibodies in Acute Coronary Syndrome: Is Less Sometimes More? Front Cardiovasc Med, 5, 170 (2018)
DOI: 10.3389/fcvm.2018.00170

25. L. M. Giil, D. Aarsland, K. Hellton, A. Lund, H. Heidecke, K. Schulze-Forster, G. Riemekasten, A. O. Vik-Mo, E. K. Kristoffersen, C. A. Vedeler and J. E. Nordrehaug: Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimer’s Disease: A Longitudinal Study. J Alzheimers Dis, 64(3), 761-774 (2018)
DOI: 10.3233/JAD-170882

26. G. Wallukat and A. Wollenberger: Effects of the serum gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic beta adrenoceptor function in cultured neonatal rat heart myocytes. Biomed Biochim Acta, 46(8-9), S634-9 (1987)

27. J. G. O’Leary, A. J. Demetris, A. Philippe, R. Freeman, J. Cai, H. Heidecke, C. Smith, B. Hart, L. W. Jennings, R. Catar, M. Everly, G. B. Klintmalm and D. Dragun: Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts. Transplantation, 101(10), 2399-2409 (2017)
DOI: 10.1097/TP.0000000000001853

28. N. E. Hiemann, R. Meyer, E. Wellnhofer, C. Schoenemann, H. Heidecke, N. Lachmann, R. Hetzer and D. Dragun: Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation, 94(9), 919-24 (2012)
DOI: 10.1097/TP.0b013e3182692ad2

29. M. O. Becker, A. Kill, M. Kutsche, J. Guenther, A. Rose, C. Tabeling, M. Witzenrath, A. A. Kuhl, H. Heidecke, H. A. Ghofrani, H. Tiede, R. T. Schermuly, N. Nickel, M. M. Hoeper, I. Lukitsch, M. Gollasch, W. M. Kuebler, S. Bock, G. R. Burmester, D. Dragun and G. Riemekasten: Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med, 190(7), 808-17 (2014)
DOI: 10.1164/rccm.201403-0442OC

30. G. Riemekasten, A. Philippe, M. Nather, T. Slowinski, D. N. Muller, H. Heidecke, M. Matucci-Cerinic, L. Czirjak, I. Lukitsch, M. Becker, A. Kill, J. M. van Laar, R. Catar, F. C. Luft, G. R. Burmester, B. Hegner and D. Dragun: Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis, 70(3), 530-6 (2011)
DOI: 10.1136/ard.2010.135772

31. D. Dragun, D. N. Muller, J. H. Brasen, L. Fritsche, M. Nieminen-Kelha, R. Dechend, U. Kintscher, B. Rudolph, J. Hoebeke, D. Eckert, I. Mazak, R. Plehm, C. Schonemann, T. Unger, K. Budde, H. H. Neumayer, F. C. Luft and G. Wallukat: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med, 352(6), 558-69 (2005)
DOI: 10.1056/NEJMoa035717

32. J. R. Ingelfinger: Agonistic autoantibodies and rejection of renal allografts. N Engl J Med, 352(6), 617-9 (2005)
DOI: 10.1056/NEJMe048335

33. C. Liu, R. Luo, S. E. Elliott, W. Wang, N. F. Parchim, T. Iriyama, P. S. Daugherty, S. C. Blackwell, B. M. Sibai, R. E. Kellems and Y. Xia: Elevated Transglutaminase Activity Triggers Angiotensin Receptor Activating Autoantibody Production and Pathophysiology of Preeclampsia. J Am Heart Assoc, 4(12) (2015)
DOI: 10.1161/JAHA.115.002323

34. A. Lund, L. M. Giil, G. Slettom, O. Nygaard, H. Heidecke and J. E. Nordrehaug: Antibodies to receptors are associated with biomarkers of inflammation and myocardial damage in heart failure. Int J Cardiol, 250, 253-259 (2018)
DOI: 10.1016/j.ijcard.2017.10.013

35. S. Buttrup Larsen, G. Wallukat, I. Schimke, A. Sandager, T. Tvilum Christensen, N. Uldbjerg and N. Torring: Functional autoantibodies against Endothelin-1 receptor type A and Angiotensin II receptor type 1 in patients with preeclampsia. Pregnancy Hypertens, 14, 189-194 (2018)
DOI: 10.1016/j.preghy.2018.10.002

36. C. Albert, M. von Schultzendorff, D. Salaru, Z. Halloul, D. Dragun, H. Heidecke and P. R. Mertens: In arterial occlusive disease autoantibodies against ETAR and AT(1)R correlate with each other but are not associated with classical cardiovascular risk factors. Vasa, 43(2), 113-23 (2014)
DOI: 10.1024/0301-1526/a000337

37. K. Kreienbring, A. Franz, R. Richter, D. Dragun, H. Heidecke, D. Muller, M. Mentze, R. Dechend, J. Sehouli and E. I. Braicu: The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer. Anticancer Res, 38(6), 3619-3625 (2018)
DOI: 10.21873/anticanres.12636

38. F. Weigold, J. Gunther, M. Pfeiffenberger, O. Cabral-Marques, E. Siegert, D. Dragun, A. Philippe, A. K. Regensburger, A. Recke, X. Yu, F. Petersen, R. Catar, R. Biesen, F. Hiepe, G. R. Burmester, H. Heidecke and G. Riemekasten: Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis. Arthritis Res Ther, 20(1), 52 (2018)
DOI: 10.1186/s13075-018-1545-8

39. D. Ernst, C. Widera, D. Weiberg, T. Derlin, G. Ahrenstorf, G. Sogkas, A. Jablonka, R. Schmidt, T. Witte, H. Heidecke and G. Riemekasten: Beta-1-adrenergic receptor antibodies in acute coronary syndrome: is less sometimes more?, 5(170) (2018)
DOI: 10.3389/fcvm.2018.00170

40. M. Giral, Y. Foucher, A. Dufay, J. P. Van Huyen, K. Renaudin, A. Moreau, A. Philippe, B. Hegner, R. Dechend, H. Heidecke, S. Brouard, A. Cesbron, S. Castagnet, A. Devys, J. P. Soulillou and D. Dragun: Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant, 13(10), 2567-76 (2013)
DOI: 10.1111/ajt.12397

Key Words: Autoantibodies against GPCR, Preeclampsia, Adverse pregnancy outcome, Blood pressure, Cardiovascular risk

Send correspondence to: Ralf Dechend, MD, Experimental and Clinical Research Center (ECRC), Lindenberger Weg 80, 13125 Berlin, Germany, Tel:  49 30 450 540301, Fax: 49-30-450540944, E-mail: ralf.dechend@charite.de